| Date | Title | | | Dec.28.11 | Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference|
PARSIPPANY, N.J., Dec. 28, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 7:30 am Pacific Standard Time (10:30 am Eastern Standard Time) at the Westin St. Francis in San Francisco, California. T... |
|  | | Dec.22.11 | Watson to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top|
PARSIPPANY, N.J., Dec. 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 5, 2012 at 1:45 pm Eastern Time at the Goldman Sachs Conference Center in New York, New York. The presentation will... |
| | | Dec.19.11 | Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars|
THOUSAND OAKS, Calif. and PARISIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines. This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expe... |
| | | Dec.08.11 | Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder| -- Novel Formulation Provides Convenience, Efficacy and Excellent Tolerability
-- Watson to Launch Product in Spring 2012 --
PARSIPPANY, N.J. and EWING, N.J., Dec. 8, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today announced that the U.S. Food and Drug Administration (FDA) has approved Antares' topical oxybutynin gel 3% product for the treatment of overactive bladder (OAB) with symptoms of urge urinary incont... |
| | | Dec.07.11 | Watson Launches Generic LoSEASONIQUE(R)| PARSIPPANY, N.J., Dec. 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy. Terms of the settlement were not disclosed.
As a "first applicant" to s... |
| | | Nov.30.11 | Watson Launches Generic LIPITOR(R)| - Largest generic product launch in US history -
PARSIPPANY, N.J., Nov. 30, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Watson Pharmaceuticals, Inc., has launched an authorized generic version of LIPITOR® (atorvastatin calcium tablets) as part of an exclusive agreement with Pfizer Inc. Watson began shipping the product today. LIPITOR® is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL, triglycerides and to ... |
| | | Nov.29.11 | Watson's Generic Yaz(R) Receives FDA Approval|
PARSIPPANY, N.J., Nov. 29, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz(R) oral contraceptive product. Watson is currently involved in patent litigation with Bayer concerning this product.
Yaz(R... |
| | | Nov.21.11 | Watson to Present at the 2011 Piper Jaffray Health Care Conference|
PARSIPPANY, N.J., Nov. 21, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Piper Jaffray Health Care Conference on Wednesday, November 30, 2011 at 9:30 am EST at the New York Palace Hotel in New York. The presentation will be webcast live and can be accessed on Watson Pharmaceutic... |
| | | Nov.16.11 | Watson Wins Kentucky Drug Pricing Litigation|
PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that a jury in the drug pricing litigation trial in the Kentucky Circuit Court for Franklin County rendered a verdict in favor of Watson on all counts in the litigation.
Beginning in July 2002, the Company and certain of its subsidiaries, as well as numerous other pharmaceutical companies, were named as defendants in various states and federal court actions including the case decided to... |
| | | Nov.10.11 | Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA| Advisory Committee for Reproductive Health Drugs Meeting Scheduled for January 20, 2012
LIVINGSTON, N.J. and PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire via COMTEX/ --Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the Advisory Committee for Reproductive Health Drugs of the U.S. Food and Drug Administration (FDA) is scheduled to review Columbia's New Drug Application (NDA) for progesterone vaginal gel for the reduction of risk of ... |
| | | Nov.10.11 | Watson' Launches Generic Kadian(R)| PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian®. Watson began shipping the product today. Kadian® is indicated to manage moderate to severe pain that continues around-the-clock and is expected to last f... |
| | | Nov.10.11 | Watson Confirms Exelon(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr. Watson's rivastigmine transdermal system patch is a generic version of Novartis' Exelon(R) Patch. Ex... |
| | | Nov.10.11 | Watson Confirms Appeals Court Decision Rejecting Teva's Motion to Enjoin Watson's Sales of Generic SEASONIQUE®| PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit affirmed the district court's June 16, 2011 denial of Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction to prevent Watson from selling generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg)). Watson launched Amethia(TM) (levonorgestrel/ethinyl estradio... |
| | | Nov.01.11 | Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54|
- 31% Increase in Non-GAAP Net Income -
- 22% Increase in Adjusted EBITDA -
- Company Increases Full Year 2011 Forecast -
PARSIPPANY, N.J., Nov. 1, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million o... |
| | | Oct.28.11 | Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®| PARSIPPANY, N.J., Oct. 28, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX®. The Company said that it was reviewing the ... |
| | | Oct.28.11 | Watson to Present at the 2011 Annual Credit Suisse Health Care Conference| PARSIPPANY, N.J., Oct. 28, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Annual Credit Suisse Health Care Conference on Wednesday, November 9, 2011 at 8:00 am MST (10:00 am EST) at the Arizona Biltmore Hotel in Phoenix. The presentation will be webcast live and can be acce... |
| | | Oct.21.11 | FDA Approves Watson's Androderm® (testosterone transdermal system) 2 mg/day and 4 mg/day| New formulation represents 20% reduction in active ingredient; smaller patch size -
PARSIPPANY, N.J., Oct. 21, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. Food and Drug Administration (FDA) approved its Androderm® (testosterone transdermal system) 2 mg and 4 mg formulation. The new smaller size and lower-dose testosterone patch provides highly effective testosterone administration with a 20 percent reduction in the active ingredient ... |
| | | Oct.17.11 | Watson Confirms Atelvia(TM) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Oct. 17, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Risedronate Sodium Delayed-release Tablets, 35 mg. Watson's Risedronate Sodium Delayed-release Tablets are a generic version of Warner Chilcott (US), LLC's Atelvi... |
| | | Oct.14.11 | Watson Confirms Daytrana(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Oct. 14, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Methylphenidate Transdermal System, 10 mg/9 hrs, 15 mg/9 hrs, 20 mg/9 hrs, and 30 mg/9 hrs. Watson's Methylphenidate Transdermal System products are generic versions of Nov... |
| | | Oct.08.11 | Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®| PARSIPPANY, N.J., Oct. 8, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Massachusetts has granted a request by Momenta Pharmaceuticals, Inc. and Sandoz Inc. for a temporary restraining order (TRO) preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection product, a generic equivalent to Sanofi-aventis' LOVENOX®. The temporary restraini... |
| | | Oct.07.11 | Watson Confirms EMBEDA(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Oct. 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Morphine Sulfate and Naltrexone Hydrochloride Extended-release Capsules 30 mg/1.2 mg, 50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and 100 mg/4 mg. Watson's Morphine Su... |
| | | Oct.07.11 | Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)| PARSIPPANY, N.J., Oct. 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Massachusetts has granted a request by Momenta Pharmaceuticals, Inc. and Sandoz Inc. for a temporary restraining order (TRO) preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection product, a generic equivalent to Sanofi-aventis' LOVENOX®. The temporary restraini... |
| | | Sep.26.11 | Watson Launches Generic FEMCON(R) Fe| PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched Norethindrone and Ethinyl Estradiol Tablets (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets (Chewable), 75 mg, a generic version of Warner Chilcott's FEMCON(R) Fe. Watson began shipping the product today. FEMCON(R) Fe is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
For the most rece... |
| | | Sep.23.11 | Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings| PARSIPPANY, N.J., Sept. 23, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, announced today that the Company intends to release its third quarter 2011 financial results on Tuesday, November 1, 2011 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on November 1, 2011 to discuss its financial results and provide an update on the Company's ... |
| | | Sep.22.11 | Watson Confirms Amphastar Patent Lawsuit| PARSIPPANY, N.J., Sept. 22, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, Inc. and Watson on September 21, 2011 in the United States District Court for the District of Massachusetts. The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the U.S. retail pharmacy channel, infringes Mom... |
| | | Sep.22.11 | Watson to Present at the Jefferies 2011 Global Healthcare Conference| PARSIPPANY, N.J., Sept. 22, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Siggi Olafsson, Watson's Executive Vice President, Global Generics, will provide an overview and update of the Company's business at the Jefferies 2011 Global Healthcare Conference on Tuesday, September 27, 2011 at 9:20 am BST (4:20 am EDT) in London, England. The presentation will be webcast live and can be accessed on Watson Pharm... |
| | | Sep.19.11 | Watson Pharmaceuticals Announces Approval of Amphastar's Generic LOVENOX(R)| Fourth Quarter Launch Planned-
PARSIPPANY, N.J., Sept. 19, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration ("FDA") approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 100mg/mL and 150mg/mL strengths. Enoxaparin Sodium Injection is the generic equivalent to Sanofi-aventis' LOVENOX®, and is a low molecular weight heparin indica... |
| | | Sep.13.11 | Watson Launches Generic Keppra XR®| MORRISTOWN, N.J., Sept. 13, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. has launched Levetiracetam Extended-Release 500 mg and 750 mg tablets, the generic version of UCB, Inc.'s Keppra XR® following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). Watson has begun shipping the product today. Keppra XR® is indicated to treat partial onset seizures in ... |
| | | Sep.01.11 | Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference| PARSIPPANY, N.J., Sept. 1, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Bank of America Merrill Lynch Global Healthcare Conference on Thursday, September 15, 2011 at 8:55 am BST (3:55 am EDT) at Merrill Lynch Financial Center, London. The presentation will be webcast live ... |
| | | Aug.30.11 | Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference| PARSIPPANY, N.J., Aug. 30, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2011 at 1:35 pm Eastern Time at the Grand Hyatt New York in New York City. The presentation will be webcast live and can be access... |
| | | Aug.11.11 | Watson's Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS| Credits Partnership with Governor, Mississippi Development Authority In Decision to Invest $23.5 Million in Facility; Create Approximately 70 Jobs
PARSIPPANY, N.J., Aug. 11, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its Anda Distribution division will construct a 234,000 square foot, state-of-the-art pharmaceutical distribution facility in Olive Branch, DeSoto County, MS. The Company said the facility, which is expected to begin operation in... |
| | | Aug.10.11 | Watson's Rosuvastatin Zinc Tablets Receive Tentative FDA Approval| MORRISTOWN, N.J., Aug. 10, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received tentative approval from the United States Food and Drug Administration (FDA) for its rosuvastatin zinc 5, 10, 20 and 40 mg tablets. Watson's rosuvastatin zinc tablets are a new salt form of AstraZeneca's Crestor® (rosuvastatin calcium) tablets.
On July 15, 2010, Watson Laboratories, Inc., filed a New Drug Application (N... |
| | | Jul.28.11 | Watson Launches Generic Seasonique(R)| PARSIPPANY, N.J., July 28, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has launched Amethia(TM) (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg)), the generic equivalent of Duramed Pharmaceuticals Inc.'s Seasonique(R). Watson began shipping the product today, following a denial by the United States Court of Appeals for the Federal Circuit of a request for a temporary inj... |
| | | Jul.26.11 | Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01|
- 24% Increase in Net Revenue and Non-GAAP Net Income -
- 17% Increase in Adjusted EBITDA -
- Company Increases Full Year 2011 Revenue and Earnings Forecast -
PARSIPPANY, N.J., July 26, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue of $1.1 billion for the second quarter ended June 30, 2011, an increase of 24 percent when compared to $875.3 million in the second quarter 2010. On a non-GAAP basis, net income for the second quarter 2011 incr... |
| | | Jul.26.11 | Watson Enters into Agreement to Acquire Products Related to Perrigo's Acquisition of Paddock Laboratories| PARSIPPANY, N.J., July 26, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories. The portfolio consists of six products, including four FDA-approved products and two undisclosed development-stage products. Commercialized products in the portfolio include:
Ciclopirox shampoo 1% ... |
| | | Jul.22.11 | Watson Confirms JALYN(TM) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., July 22, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market dutasteride and tamsulosin hydrochloride capsules. Watson's dutasteride and tamsulosin hydrochloride capsules are a generic version of GlaxoSmithKline's JALYN(TM)... |
| | | Jul.11.11 | Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))| Late Stage Development Product Further Extends Watson's Overactive Bladder Portfolio --
PARSIPPANY, N.J. and EWING, N.J., July 11, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada. A New Drug Application for the oxybutynin gel product is currently under review by the Food and Drug Admi... |
| | | Jul.07.11 | Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit| PARSIPPANY, N.J., July 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the Southern District of Florida's February 2011 decision that Watson's generic versions of Mucinex(R) (Guaifenesin), Mucinex(R) D (Pseudoephedrine/Guaifenesin), and Mucinex(R) DM (Dextromethorphan HBr/ Guaifenesin) Extended-Release products do not infringe U.S. Patent No... |
| | | Jul.07.11 | Watson Confirms Vyvanse(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., July 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market lisdexamfetamine dimesylate capsules. Watson's lisdexamfetamine dimesylate capsules are a generic version of Shire LLC's Vyvanse®. Vyvanse® is a prescription medicine for th... |
| | | Jun.30.11 | Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings| PARSIPPANY, N.J., June 30, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, announced today that the Company intends to release its second quarter 2011 financial results on Tuesday, July 26, 2011 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on July 26, 2011 to discuss its financial results and provide an update on the Company's outloo... |
| | | Jun.27.11 | Columbia Laboratories' NDA for PROCHIEVE(R) Vaginal Progesterone Gel Accepted for Filing by FDA| LIVINGSTON, N.J. and MORRISTOWN, N.J., June 27, 2011 /PRNewswire via COMTEX/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) and Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Columbia's New Drug Application (NDA) for PROCHIEVE(R) (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. The acceptance of the NDA for filing means FDA ... |
| | | Jun.22.11 | Watson Announces Expansion of Salt Lake City, Utah Pharmaceutical R&D and Manufacturing Facility| Governor Gary R. Herbert Participates in Ground Breaking Ceremony -
SALT LAKE CITY, June 22, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today formally announced an approximately $44 million expansion of its Salt Lake City, Utah, Watson Laboratories, Inc. site. This facility is Watson's state-of-the-art pharmaceutical research, development and manufacturing facility for transdermal patches and topical gels. Governor Gary R. Herbert toured the facility and partic... |
| | | Jun.20.11 | Watson to Present at 2011 Wells Fargo Securities Healthcare Conference| PARSIPPANY, N.J., June 20, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Siggi Olafsson, Executive Vice President, Global Generics, will provide an overview and update of the Company's business at the 2011 Wells Fargo Securities Healthcare Conference on Thursday, June 23, 2011 at 8:00am Eastern Time at the InterContinental Boston in Boston, Massachusetts. The presentation will be webcast live and can be ... |
| | | Jun.20.11 | Watson Confirms AVODART(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., June 20, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dutasteride Capsules, 0.5 mg. Watson's Dutasteride Capsules product is a generic version of GlaxoSmithKline's AVODART(R), which is indicated for the treatment of sy... |
| | | Jun.17.11 | Watson Confirms Court Decision Rejecting Teva's Motion to Prevent Launch of Generic SEASONIQUE(R)| PARSIPPANY, N.J., June 17, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg). The compan... |
| | | Jun.17.11 | Watson's Nabumetone Tablets Receive FDA Approval| PARSIPPANY, N.J., June 17, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 mg and 750 mg. Watson expects to launch the product shortly.
Nabumetone had total U.S. sales of $58 million for the twelve months ending April 30, 2011, according to IMS Health. Nabumetone is indicated for the relief of... |
| | | Jun.14.11 | Watson Confirms Pataday(TM) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., June 14, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%. Watson's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is a generic version of Alcon, Inc.'s Pataday(TM) ... |
| | | Jun.07.11 | Watson's Generic Lybrel(R) Receives FDA Approval| PARSIPPANY, N.J., June 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09 mg/0.02 mg, the generic equivalent to Pfizer's Lybrel® tablets. Watson expects to launch the product shortly.
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )
Lybrel® had tota... |
| | | Jun.02.11 | Watson Confirms Viagra(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., June 2, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Sildenafil Citrate Tablets, 25, 50 and 100 mg. Watson's Sildenafil Citrate tablets are a generic version of Pfizer Inc.'s Viagra®, which is indicated for the treatment of ere... |
| | | Jun.01.11 | Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference| PARSIPPANY, N.J., June 1, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 at 11:00am Eastern Time at the Terranea Resort in Rancho Palos Verdes, California. The presentation will be webcast liv... |
| | | May.25.11 | Watson Acquires Specifar Pharmaceuticals|
- Adds Leading Pan-European Generic Development Business
- Enhances Watson's Commercial Capabilities in Key European Markets By Providing a Portfolio of Approved Products
- Expands Watson's Commercial Presence into EUR 6 Billion Greek Market
- Expected to be Immediately Accretive to Non-GAAP Earnings
- Esomeprazole Tablets in Development for International Markets Offers Upside Potential
- Adds Experienced European Management Team as well as Flexibility and Capabilities to Watson's Global ... |
| | | May.17.11 | Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome|
- Treatment Reduces Symptoms and Improves Quality of Life -
- RAPAFLO(R) demonstrated significant response in men with moderate to severe CP/CPPS -
WASHINGTON, May 17, 2011 /PRNewswire via COMTEX/ --New data presented today show that RAPAFLO(R) (silodosin) significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). In the study presented at the annual meeting of the American Urological Association, RAPAFLO(R) also significantly improved u... |
| | | May.16.11 | Watson Launches Generic AMRIX (R)| PARSIPPANY, N.J., May 16, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc. AMRIX is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal condi... |
| | | May.02.11 | Watson Launches Generic Concerta (R)| PARSIPPANY, N.J., May 2, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., has launched an authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets) as part of an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI). Watson began shipping the product today. Concerta is approved for the treatment of attention deficit hyperactivity disorder (ADHD) in... |
| | | May.02.11 | Watson's Generess(TM) Fe, Unique, Low-Dose Oral Contraceptive Launched| "I am Generess(TM)" Companion Program Features Patient Cost Savings, Women's Charity Donation -
PARSIPPANY, N.J., May 2, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. commercial launch of Generess(TM) Fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lig... |
| | | Apr.29.11 | Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th| PARSIPPANY, N.J., April 29, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), an integrated global specialty pharmaceutical company, announced today that the Company will conduct a live webcast of its 2011 Annual Meeting of Stockholders on Friday May 13, 2011 beginning at 9:00 AM Eastern Daylight Time. As part of the meeting, Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business.
The webcast can be a... |
| | | Apr.27.11 | Watson First Quarter 2011 Net Revenue Increases to $877 Million|
- First Quarter 2011 Non-GAAP EPS up 10% to $0.89 -
- Company Increases 2011 Earnings Forecast -
PARSIPPANY, N.J., April 27, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue of $876.5 million for the first quarter ended March 31, 2011, compared to $856.5 million in the first quarter 2010. On a non-GAAP basis, net income for the first quarter 2011 was $111.9 million or $0.89 per share, an increase of 12 percent, compared to $100.3 million or $... |
| | | Apr.26.11 | Columbia Laboratories Submits NDA for PROCHIEVE(R) Vaginal Progesterone Gel| LIVINGSTON and PARSIPPANY, N.J., April 26, 2011 /PRNewswire via COMTEX/ --Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that Columbia has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PROCHIEVE(R) (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy.
In the submission, Columbia requested Priority Review... |
| | | Apr.20.11 | Watson Confirms Welchol(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., April 20, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colesevelam HCI 625 mg tablets. Watson's Colesevelam HCI tablets are a generic version of Daiichi Sankyo, Inc.'s Welchol(R).
Daiichi Sankyo and Genzyme Corporation filed... |
| | | Apr.13.11 | Watson Designates Parsippany, NJ Facility as Corporate Headquarters| New Parsippany Facility Supports Global Expansion; Unites NJ Operations in Single Location -
PARSIPPANY, N.J., April 13, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has formally designated its Parsippany, New Jersey facility as its Corporate Headquarters. The Company's new Corporate Headquarters address is Morris Corporate Center III, 400 Interpace Parkway, Parsippany, NJ 07054.
Previously, Watson Corporate Headquarters was located at ... |
| | | Apr.08.11 | Watson Confirms Vigamox(R) Patent Challenge| Paragraph IV Litigation Underway-
PARSIPPANY, N.J., April 8, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%. Watson's Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon, Inc.'s Vigamox(R), ... |
| | | Apr.06.11 | Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE(R) Vaginal Progesterone Gel Study Results| Data Demonstrate a Significantly Lower Rate of Preterm Birth before 33 Weeks Gestation among Women with a Shortened Cervix treated with PROCHIEVE vs. Placebo
LIVINGSTON and MORRISTOWN, N.J., April 6, 2011 /PRNewswire via COMTEX/ --Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the publication of Phase III PROCHIEVE(R) (progesterone gel) data in today's online version of Ultrasound in Obstetrics & Gynecology, the leading peer-revie... |
| | | Apr.05.11 | Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings| PARSIPPANY, N.J., April 5, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, announced today that the Company intends to release its first quarter 2011 financial results on Wednesday, April 27, 2011 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on April 27, 2011 to discuss its financial results and provide an update on the Company's outl... |
| | | Mar.31.11 | Watson Announces Approval of Nulecit(TM), the First Generic Alternative to Ferrlecit(R) for the Treatment of Iron Deficiency Anemia| MORRISTOWN, N.J., March 31, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it is initiating launch activities of Nulecit(TM) (sodium ferric gluconate complex in sucrose injection), following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application (ANDA). Nulecit is the first bioequivalent and therapeutically equivalent alternative to Sanofi-Aventis' Ferrlecit(R). In July 2009 Watson signed a license agreement with GeneraMedix for the exc... |
| | | Mar.25.11 | Watson Confirms District Court Ruling in Generic Fentora(R) Patent Suit| MORRISTOWN, N.J., March 25, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora(R) (fentanyl buccal tablets C-II) infringes United States Patent No. 6,264,981 (the '981 Patent). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.
Watson's Abbreviated New Drug Applicati... |
| | | Mar.25.11 | Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE(R) Patent Challenge| MORRISTOWN, N.J., March 25, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that it has received a favorable decision from the U.S. Court of Appeals for the Federal Circuit related to its ongoing patent challenge in connection with Watson's Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic version of Teva Women's Health, Inc.'s SEASONIQUE(R)(levonorgestrel/ethinyl estradiol... |
| | | Mar.25.11 | Watson Confirms OxyContin(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., March 25, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiaries, Andrx Labs, LLC and Watson Laboratories, Inc. -- Florida, (collectively "Watson") filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxycodone Hydrochloride Extended-Release tablets in the 10,15, 20, 30, 40, 60 and 80 mg strengths. Watson's Oxycodon... |
| | | Mar.21.11 | Watson Launches Generic Famvir(R)| MORRISTOWN, N.J., March 21, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. has launched Famciclovir tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir(R) following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). Watson has begun shipping the product today. Famciclovir is an antiviral used in the treatment for immunocompetent adul... |
| | | Mar.14.11 | Watson Announces Favorable District Court Ruling in Generic Fentora(R) Patent Suit| MORRISTOWN, N.J., March 14, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora(R) (fentanyl buccal tablets C-II) does not infringe United States Patent Nos. 6,200,604 or 6,974,590 (the '604 and '590 Patents) and that the '604 and '590 Patents are invalid. A decision on United States Patent No. 6,264,981 remains outstanding and Watson remains ... |
| | | Mar.09.11 | Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President| MORRISTOWN, N.J., March 9, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a global integrated pharmaceutical company, announced today that David A. Buchen has been promoted to Executive Vice President, General Counsel and Secretary, and R. Todd Joyce has been promoted to Executive Vice President, Chief Financial Officer. Both continue to report to Paul M. Bisaro, President and Chief Executive Officer.
"These promotions not only recognize the substantial individual ... |
| | | Mar.08.11 | Watson to Present at the Barclay's 2011 Global Healthcare Conference| MORRISTOWN, N.J., March 8, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Barclay's 2011 Global Healthcare Conferenceon Tuesday, March 15, 2011 at 9:30a.m. (EDT). The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at h... |
| | | Mar.01.11 | Watson to Present at the Cowen & Company 31st Annual Healthcare Conference| MORRISTOWN, N.J., March 2, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Todd Joyce, Watson's Senior Vice President and Chief Financial Officer, will provide an overview and update of the Company's business at the Cowen & Company 31st Annual Healthcare Conferenceon Tuesday, March 8, 2011 at 9:30 a.m. Eastern time. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Inv... |
| | | Feb.23.11 | Watson to Present at the 2011 Citi Global Healthcare Conference| MORRISTOWN, N.J., Feb. 23, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Citi Global Healthcare Conferenceon Tuesday, March 1, 2011 at 1:30 p.m. (EST). The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://... |
| | | Feb.15.11 | Watson Fourth Quarter 2010 Net Revenue Increases 21% to $953 Million|
-- Fourth Quarter 2010 Non-GAAP EPS $0.93
-- Full Year 2010 Net Revenues of $3.6 Billion
-- Full Year 2010 Non-GAAP EPS $3.42
MORRISTOWN, N.J., Feb. 15, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue increased 21 percent to $952.7 million for the fourth quarter ended December 31, 2010, compared to $785.7 million in the fourth quarter 2009. On a non-GAAP basis, net income for the fourth quarter 2010 was $116.5 million or $0.93 per share, an... |
| | | Feb.09.11 | Watson Announces Favorable District Court Ruling in Generic Mucinex(R) Patent Suit| MORRISTOWN, N.J., Feb. 9, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida has ruled that Watson's generic versions of Mucinex(R), Mucinex(R) D and Mucinex(R) DM (Guaifenesin, Dextromethorphan HBr/ Guaifenesin, and Pseudoephedrine/Guaifenesin) Extended-Release products, do not infringe U.S. Patent No. 6,372,252 (the "'252 Patent").
Th... |
| | | Feb.07.11 | Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings| MORRISTOWN, N.J., Feb. 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its fourth quarter 2010 financial results on Tuesday, February 15, 2011 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on February 15, 2011 to discuss its financial results and provide an update on the Company's outlook ... |
| | | Jan.25.11 | Watson Confirms Welchol(R) Oral Suspension Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., Jan. 25, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colesevelam HCI powder for oral suspension, 1.875 gm/packet and 3.75 gm/packet. Watson's Colesevelam HCI powder for oral suspension is a generic version of Daiichi Sankyo, I... |
| | | Jan.21.11 | Watson Presents Outlook for Continued Long Term Growth| 2011 Revenue Forecasted to be $4.2 Billion; Adjusted Cash EPS of $3.85 to $4.15 and Adjusted EBITDA of $925 Million to $1.0 Billion -
NEW YORK, Jan. 21, 2011 /PRNewswire via COMTEX/ --During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. (NYSE: WPI) provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements... |
| | | Jan.12.11 | Watson Announces Preliminary Financial Performance for FY 2010|
- 2010 Net Revenue Estimated to Exceed $3.5 Billion -
- Company to Provide 2011 Outlook at January 21st Investor Day -
SAN FRANCISCO, Jan. 12, 2011 /PRNewswire via COMTEX/ --At the 29th Annual J.P. Morgan Healthcare Conference, Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that based on a preliminary review of 2010 results, it expects net revenues to increase more than 25 percent to more than $3.5 billion compared to 2009. Adjusted cash earnings per share is expected to be at or s... |
| | | Jan.10.11 | Watson's Generic Fentora(R) Receives FDA Approval| MORRISTOWN, N.J., Jan. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Fentanyl Buccal tablets, USP, in the 0.1, 0.2, 0.4, 0.6 and 0.8 mg strengths, the generic equivalent to Cephalon's Fentora (R) tablets.
Watson's Abbreviated New Drug Application (ANDA) for its generic version of FENTORA(R) is the first generic appl... |
| | | Jan.10.11 | Watson to Host Investor Day on January 21 in New York City| MORRISTOWN, N.J., Jan. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it will be hosting an Investor Day on January 21, 2011 in New York City. The presentations are scheduled to begin at 8:30 a.m., Eastern Time and will be simultaneously webcast.
At the meeting, the Company plans to provide a preliminary outlook for 2011. The presenters will include: Paul Bisaro, Watson's President and CEO; Todd Joyce, Senior Vice President and CFO; Sigurd O... |
| |
|
Country websites